Korro Bio
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $208M
Investors
- 15
About Korro Bio
Founded in 2018 by co-founders Andrew Fraley and Nessan Bermingham and based in Massachusetts, US, Korro Bio, Inc. develops genetic therapeutics through targeted RNA editing. In April 2024, Korro Bio, Inc. Iyar. The company's products are in the research and development phase, focusing on utilizing Oligonucleotide Promoted Editing of RNA (OPERA) to create new RNA-based therapies for patients with debilitating and life-threatening illnesses.
Who invested in Korro Bio
15 investors across 2 rounds
See all investors in Korro Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Korro Bio
Who invested in Korro Bio?
Korro Bio has 15 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Korro Bio raised?
Korro Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Korro Bio last raise money?
Korro Bio's most recent round on record is a Series B, in Jan 2022.
What does Korro Bio do?
Founded in 2018 by co-founders Andrew Fraley and Nessan Bermingham and based in Massachusetts, US, Korro Bio, Inc.
Where is Korro Bio headquartered?
Korro Bio is headquartered in Cambridge, US.
Which VCs invest in companies like Korro Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Korro Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Korro Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.